Treatment of manic phases of bipolar disorder: Critical synthesis of international guidelines;Traitement du trouble bipolaire en phase maniaque: Synthèse critique des recommandations internationales

Encephale

Volumn 40, Issue 4, 2014, Pages 330-337

  Geoffroy, P A ^a,b,c,g   Bellivier, F ^a,b,c,g   Henry, C ^d,e,f,g  

^a INSERM   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d FACULTÉ DE MÉDECINE   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f INSERM U955   (France)

^g FONDATION FONDAMENTAL   (France)

Author keywords

Bipolar disorder; Guidelines; Mania; Manic episode; Mood stabilizer; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; LITHIUM; MOOD STABILIZER; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ANTICONVULSIVE AGENT; NEUROLEPTIC AGENT; TRANQUILIZER;

ALGORITHM; ARTICLE; BIPOLAR DISORDER; BIPOLAR MANIA; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; DRUG WITHDRAWAL; HUMAN; MEDICAL DECISION MAKING; MONOTHERAPY; PRACTICE GUIDELINE; TREATMENT DURATION; TREATMENT INDICATION; ADOLESCENT; ADULT; CROSS-SECTIONAL STUDY; DECISION SUPPORT SYSTEM; DISABILITY; DRUG COMBINATION; FEMALE; MALE; PERSONALIZED MEDICINE; PSYCHOLOGY; RECURRENT DISEASE; YOUNG ADULT;

ADOLESCENT; ADULT; ALGORITHMS; ANTICONVULSANTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CROSS-SECTIONAL STUDIES; DECISION SUPPORT TECHNIQUES; DISABILITY EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; GUIDELINE ADHERENCE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; RECURRENCE; YOUNG ADULT;

EID: 84921932833     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2013.10.007     Document Type: Article

References (54)

1. Murray C, Lopez A. The global burden of disease. A compre-hensive assessment of morbidity and disability from diseases,injuries and risk factors in 1990 and projected to 2020. Cam-bridge, Massachusetts: Harvard University Press; 1996
2. Geoffroy PA, Etain B, Scott J, et al. Reconsideration of bipolardisorder as a developmental disorder: importance of the timeof onset. J Physiol Paris 2013;107(4):278-85
3. Scott J, Leboyer M. Consequences of delayed diagnosis of bipo-lar disorders. Encéphale 2011;37(Suppl. 3):S173-5
4. NICE. Bipolar disorder. NICE; 2006 [Internet, cité 28 janv 2012]http://www.nice.org.uk/
5. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Networkfor Mood and Anxiety Treatments (CANMAT) and Internatio-nal Society for Bipolar Disorders (ISBD) collaborative updateof CANMAT guidelines for the management of patients withbipolar disorder: update 2009. Bipolar Disord 2009;11(3):225-55
6. Grunze H, Vieta E, Goodwin GM, et al. The World Federa-tion of Societies of Biological Psychiatry (WFSBP) guidelinesfor the biological treatment of bipolar disorders: update2009 on the treatment of acute mania. World J Biol Psychiatry2009;10(2):85-116
7. Goodwin GM. Evidence-based guidelines for treating bipolardisorder: revised second edition-recommendations from theBritish Association for Psychopharmacology. J Psychopharmacol(Oxford) 2009;23(4):346-88
8. Malhi GS, Adams D, Lampe L, et al. Clinical practice recom-mendations for bipolar disorder. Acta Psychiatr Scand Suppl2009;(439):27-46
9. American Psychiatric Association. Practice guideline for thetreatment of patients with bipolar disorder (revision). Am JPsychiatry 2002;159(Suppl. 4):1-50
10. Grunze H, Kasper S, Goodwin G, et al. The World Federationof Societies of Biological Psychiatry (WFSBP) guidelines for thebiological treatment of bipolar disorders, part II: treatment ofmania. World J Biol Psychiatry 2003;4(1):5-13
11. Grunze H, Kasper S, Goodwin G, et al. The World Federa-tion of Societies of Biological Psychiatry (WFSBP) guidelinesfor the biological treatment of bipolar disorders, part III:maintenance treatment. World J Biol Psychiatry 2004;5(3):120-35
12. Goodwin GM. Evidence-based guidelines for treating bipo-lar disorder: recommendations from the British Associationfor Psychopharmacology. J Psychopharmacol 2003;17(2):149-73
13. Llorca P-M, Courtet P, Martin P, et al. [Screening and manage-ment of bipolar disorders: results]. Encéphale 2010;36(Suppl.4):S86-102
14. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Networkfor Mood and Anxiety Treatments (CANMAT) guidelines for themanagement of patients with bipolar disorder: consensus andcontroversies. Bipolar Disord 2005;7(Suppl. 3):5-69
15. HAS. Troubles Bipolaires. Guide Médecin 2009;AL23:1-74
16. Johnson FR, Ozdemir S, Manjunath R, et al. Factors that affectadherence to bipolar disorder treatments: a stated-preferenceapproach. Med Care 2007;45(6):545-52
17. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrencein bipolar disorder: primary outcomes from the SystematicTreatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006;163(2):217-24
18. Schneck CD, Miklowitz DJ, Miyahara S, et al. The prospec-tive course of rapid-cycling bipolar disorder: findings from theSTEP-BD. Am J Psychiatry 2008;165(3):370-7
19. McKnight RF, Adida M, Budge K, et al. Lithium toxi-city profile: a systematic review and meta-analysis. Lancet2012;379(9817):721-8
20. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs.Lancet Neurol 2012;11(9):803-13
21. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A12-week, double-blind comparison of olanzapine vs halope-ridol in the treatment of acute mania. Arch Gen Psychiatry2003;60(12):1218-26
22. Geoffroy PA, Etain B, Henry C, et al. Combination therapy formanic phases: a critical review of a common practice. CNSNeurosci Ther 2012;18(12):957-64
23. Nivoli AMA, Murru A, Goikolea JM, et al. New treatment guide-lines for acute bipolar mania: a critical review. J Affect Disord2012;140(2):125-41
24. Lim PZ, Tunis SL, Edell WS, et al. Medication prescribing pat-terns for patients with bipolar I disorder in hospital settings:adherence to published practice guidelines. Bipolar Disord2001;3(4):165-73
25. Wolfsperger M, Greil W, Rössler W, et al. Pharmacologicaltreatment of acute mania in psychiatric in-patients between1994 and 2004. J Affect Disord 2007;99(1-3):9-17
26. Haro JM, Reed C, Gonzalez-Pinto A, et al. 2-Year course ofbipolar disorder type I patients in outpatient care: factorsassociated with remission and functional recovery. Eur Neu-ropsychopharmacol 2011;21(4):287-93
27. Cookson J. Use of antipsychotic drugs and lithium in mania. BrJ Psychiatry 2001;178(Suppl. 41):S148-56
28. Smith LA, Cornelius V, Warnock A, et al. Pharmacologi-cal interventions for acute bipolar mania: a systematicreview of randomized placebo-controlled trials. Bipolar Disord2007;9(6):551-60
29. Garfinkel PE, Stancer HC, Persad E. A comparison of haloperi-dol, lithium carbonate and their combination in the treatmentof mania. J Affect Disord 1980;2(4):279-88
30. Klein E, Bental E, Lerer B, et al. Carbamazepine and halo-peridol v placebo and haloperidol in excited psychoses. Acontrolled study. Arch Gen Psychiatry 1984;41(2):165-70
31. Muller AA, Stoll KD. Carbamazepine and oxcarbazepine in thetreatment of manic syndromes: studies in Germany. In: EmrichHM, Okuma T, Muller AA, editors. Anticonvulsants in affectivedisorders. Amsterdam, Netherlands: Excerpta Medica; 1984. p.134-47
32. Desai NG, Gangadhar BN, Channabasavanna SM,et al.Carbamazepine hastens therapeutic action of lithiumin mania. Proceedings international conference on newdirections in affective disorders. 1987. p. 97 [Abstract
33. Möller HJ, Kissling W, Riehl T, et al. Double-blind evaluation ofthe antimanic properties of carbamazepine as a comedicationto haloperidol. Prog Neuropsychopharmacol Biol Psychiatry1989;13(1-2):127-36
34. Anand A, Oren DA, Berman RM, et al. Lamotrigine treatmentof lithium failure outpatient mania: a double-blind, placebo-controlled trial. In: Scares JC, Gershon S, editors. Abstractbook on 3rd international conference on bipolar disorder (p.23). Pittsburgh, PA. Copenhagen: Munksgaard; 1999
35. Müller-Oerlinghausen B, Retzow A, et al. Valproate as anadjunct to neuroleptic medication for the treatment of acuteepisodes of mania: a prospective, randomized, double-blind,placebo-controlled, multicenter study. J Clin Psychopharmacol2000;20(2):195-203
36. Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipo-lar disorder: a placebo-controlled trial of adjunctive therapy.Bipolar Disord 2000;2(3 Pt 2):249-55
37. Sachs GS, Grossman F, Ghaemi SN, et al. Combination of amood stabilizer with risperidone or haloperidol for treatmentof acute mania: a double-blind, placebo-controlled comparisonof efficacy and safety. Am J Psychiatry 2002;159(7):1146-54
38. Tohen M, Chengappa KNR, Suppes T, et al. Efficacy of olanza-pine in combination with valproate or lithium in the treatmentof mania in patients partially nonresponsive to valproate orlithium monotherapy. Arch Gen Psychiatry 2002;59(1):62-9
39. Delbello MP, Schwiers ML, Rosenberg HL, et al. A double-blind,randomized, placebo-controlled study of quetiapine as adjunc-tive treatment for adolescent mania. J Am Acad Child AdolescPsychiatry 2002;41(10):1216-23
40. Yatham LN, Grossman F, Augustyns I, et al. Mood stabilisersplus risperidone or placebo in the treatment of acute mania.International, double-blind, randomised controlled trial. Br JPsychiatry 2003;182:141-7
41. Sachs G, Chengappa KNR, Suppes T, et al. Quetiapine withlithium or divalproex for the treatment of bipolar mania: arandomized, double-blind, placebo-controlled study. BipolarDisord 2004;6(3):213-23
42. McIntyre RS, Konarski JZ, Jones M, et al. Quetiapine in thetreatment of acute bipolar mania: efficacy across a broad rangeof symptoms. J Affect Disord 2007;100(Suppl. 1):S5-14
43. Yatham LN, Vieta E, Young AH, et al. A double-blind, ran-domized, placebo-controlled trial of quetiapine as an add-ontherapy to lithium or divalproex for the treatment of bipolarmania. Int Clin Psychopharmacol 2007;22(4):212-20
44. Vieta E, T'joen C, McQuade RD, et al. Efficacy of adjunc-tive aripiprazole to either valproate or lithium in bipolarmania patients partially nonresponsive to valproate/lithiummonotherapy: a placebo-controlled study. Am J Psychiatry2008;165(10):1316-25
45. Juruena MF, Ottoni GL, Machado-Vieira R, et al. Bipolar Iand II disorder residual symptoms: oxcarbazepine and carba-mazepine as add-on treatment to lithium in a double-blind,randomized trial. Prog Neuropsychopharmacol Biol Psychiatry2009;33(1):94-9
46. Szegedi A, Calabrese JR, Stet L, et al. Asenapine as adjunctivetreatment for acute mania associated with bipolar disorder:results of a 12-week core study and 40-week extension. J ClinPsychopharmacol 2012;32(1):46-55
47. Akhondzadeh S, Milajerdi MR, Amini H, et al. Allopurinolas an adjunct to lithium and haloperidol for treatmentof patients with acute mania: a double-blind, randomi-zed, placebo-controlled trial. Bipolar Disord 2006;8(5 Pt 1):485-9
48. Sussman N, Mullen J, Paulsson B, et al. Rates of remis-sion/euthymia with quetiapine in combination withlithium/divalproex for the treatment of acute mania. JAffect Disord 2007;100(Suppl. 1):S55-63
49. Tohen M, Bowden CL, Smulevich AB, et al. Olanzapine pluscarbamazepine v. carbamazepine alone in treating manic epi-sodes. Br J Psychiatry 2008;192(2):135-43
50. Amrollahi Z, Rezaei F, Salehi B, et al. Double-blind, rando-mized, placebo-controlled 6-week study on the efficacy andsafety of the tamoxifen adjunctive to lithium in acute bipolarmania. J Affect Disord 2011;129(1-3):327-31
51. Berwaerts J, Lane R, Nuamah IF, et al. Paliperidone extended-release as adjunctive therapy to lithium or valproate in thetreatment of acute mania: a randomized, placebo-controlledstudy. J Affect Disord 2011;129(1-3):252-60
52. Ouyang W-C, Hsu M-C, Yeh I-N, et al. Efficacy and safety ofcombination of risperidone and haloperidol with divalproatein patients with acute mania. Int J Psychiatry Clin Pract2012;16(3):178-88
53. Geoffroy PA, Etain B, Leboyer M, et al. Une entité clinique auximplications thérapeutiques majeures: le trouble bipolaire àdébut précoce. Ann Med Psychol (Paris) 2012;170(7):502-9
54. Bauer MS, Biswas K, Kilbourne AM. Enhancing multiyear gui-deline concordance for bipolar disorder through collaborativecare. Am J Psychiatry 2009;166(11):1244-50